Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)
Phase 1
Recruiting
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003127
- Lead Sponsor
- Wuhan Third Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
The confirmed patients with common type of new coronavirus pneumonia were selected, and the diagnostic criteria were shown in [diagnosis and treatment scheme 5.0 for pneumonia caused by new coronavirus infection].
Exclusion Criteria
1. Aged > 75 years old and < 18 years old;
2. Patients who are contraindicated or allergic to this study drug (lung-clearing and detoxification decoction and ulinastatin for injection);
3. Patients with previous tumor, severe liver disease, pulmonary fibrosis, tuberculosis, autoimmune diseases, and treatment with glucocorticoids and immunosuppressive agents;
4. The diagnostic criteria for severe patients with novel coronavirus pneumonia were [novel coronavirus infection pneumonia treatment scheme 5.0].
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood clotting function;ABG;liver and kidney function;blood RT;
- Secondary Outcome Measures
Name Time Method